Cancer Research Institute, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education Central South University, Hunan, PR China.
Mol Cancer. 2011 Sep 30;10:124. doi: 10.1186/1476-4598-10-124.
Perturbation of DNA methylation is frequent in cancers and has emerged as an important mechanism involved in tumorigenesis. To determine how DNA methylation is modified in the genome of primary glioma, we used Methyl-DNA immunoprecipitation (MeDIP) and Nimblegen CpG promoter microarrays to identify differentially DNA methylation sequences between primary glioma and normal brain tissue samples.
MeDIP-chip technology was used to investigate the whole-genome differential methylation patterns in glioma and normal brain tissues. Subsequently, the promoter methylation status of eight candidate genes was validated in 40 glioma samples and 4 cell lines by Sequenom's MassARRAY system. Then, the epigenetically regulated expression of these genes and the potential mechanisms were examined by chromatin immunoprecipitation and quantitative real-time PCR.
A total of 524 hypermethylated and 104 hypomethylated regions were identified in glioma. Among them, 216 hypermethylated and 60 hypomethylated regions were mapped to the promoters of known genes related to a variety of important cellular processes. Eight promoter-hypermethylated genes (ANKDD1A, GAD1, HIST1H3E, PCDHA8, PCDHA13, PHOX2B, SIX3, and SST) were confirmed in primary glioma and cell lines. Aberrant promoter methylation and changed histone modifications were associated with their reduced expression in glioma. In addition, we found loss of heterozygosity (LOH) at the miR-185 locus located in the 22q11.2 in glioma and induction of miR-185 over-expression reduced global DNA methylation and induced the expression of the promoter-hypermethylated genes in glioma cells by directly targeting the DNA methyltransferases 1.
These comprehensive data may provide new insights into the epigenetic pathogenesis of human gliomas.
DNA 甲基化的改变在癌症中很常见,并且已经成为肿瘤发生的重要机制之一。为了确定原发性神经胶质瘤基因组中的 DNA 甲基化是如何修饰的,我们使用甲基化 DNA 免疫沉淀(MeDIP)和 Nimblegen CpG 启动子微阵列来鉴定原发性神经胶质瘤和正常脑组织样本之间差异的 DNA 甲基化序列。
使用 MeDIP-chip 技术研究神经胶质瘤和正常脑组织的全基因组差异甲基化模式。随后,通过 Sequenom 的 MassARRAY 系统在 40 个神经胶质瘤样本和 4 个细胞系中验证了 8 个候选基因的启动子甲基化状态。然后,通过染色质免疫沉淀和定量实时 PCR 检测这些基因的表观遗传调控表达及其潜在机制。
在神经胶质瘤中鉴定出 524 个高甲基化和 104 个低甲基化区域。其中,216 个高甲基化和 60 个低甲基化区域映射到与各种重要细胞过程相关的已知基因的启动子上。在原发性神经胶质瘤和细胞系中证实了 8 个启动子高甲基化基因(ANKDD1A、GAD1、HIST1H3E、PCDHA8、PCDHA13、PHOX2B、SIX3 和 SST)。在神经胶质瘤中,异常的启动子甲基化和改变的组蛋白修饰与它们的表达降低有关。此外,我们发现位于 22q11.2 上的 miR-185 基因座发生杂合性缺失(LOH),并且 miR-185 的过表达通过直接靶向 DNA 甲基转移酶 1 降低了全局 DNA 甲基化并诱导了神经胶质瘤细胞中启动子高甲基化基因的表达。
这些全面的数据可能为人类神经胶质瘤的表观发病机制提供新的见解。